Breaking Finance News

Zacks Investment Research downgraded ImmunoGen, Inc. (NASDAQ:IMGN) to Sell in a report released today.

Just yesterday ImmunoGen, Inc. (NASDAQ:IMGN) traded 3.86% higher at $2.69. ImmunoGen, Inc.’s 50-day moving average is $2.84 and its 200-day moving average is $4.76. The last stock price is down -43.53% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 776,649 shares of IMGN traded hands, down from an average trading volume of 1,286,170

Zacks Investment Research has downgraded ImmunoGen, Inc. (NASDAQ:IMGN) to Sell in a report released on 10/5/2016.

Previously on 02/05/2016, Leerink Swann released a statement about ImmunoGen, Inc. (NASDAQ:IMGN) reduced the target price from $11.00 to $8.00. At the time, this indicated a possible upside of 0.23%.

See Chart Below

ImmunoGen, Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. has a 52 week low of $2.53 and a 52 week high of $14.22 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 9 firms have reported on the stock. The consensus target price is $12.61 with 4 firms rating the stock a strong buy, 1 firm rating the stock a buy, 5 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About ImmunoGen, Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.